The AI trade cooled and oil sank. A closer look at Wall Street’s volatile week
Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
Salesforce looks to strengthen its AI platform, a positive note for J&J
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery,…
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Friday’s big stock stories: What’s likely to move the market
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Wes Moss’ $1.6 Million Portfolio Rule Quietly Beats Government Pensions for Affluent Retirees
Quick Read If a $50,000 pension is worth $1 million in bond-equivalent wealth, then a $1.6 million portfolio…
The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills the Gap
Quick Read The Stocks: Johnson & Johnson (JNJ) has extended a 64-year streak of consecutive annual dividend increases…
J&J starts head-to-head PFA trial against Boston Scientific device
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free…
The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify…